Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that the number of patients treated with an antibiotic associated with a positive culture for MRSA within U.S. acute care hospitals has increased from 2006 to 2007 by 8 percent. However, the average number of days of inpatient therapy per patient treated with an antibiotic associated with a positive culture for MRSA decreased by 10 percent.

The newly released edition of The U.S. Hospital Antibiotic Market Guide finds that the most common infections among these patients with a positive culture for MRSA are:

  -- Skin/skin structure infections (46 percent of patients)   -- Systemic infections (19 percent of patients)   -- Lower respiratory infections (19 percent of patients)     Why Pharmaceutical Companies Need this Information 

The U.S. Hospital Antibiotic Market Guide allows pharmaceutical companies to quantify the clinical utilization of hospital antibiotics at a highly granular level in the United States. It is the most comprehensive data available to gain insights into clinical usage and prescriber dynamics of hospital antibiotics, including gram positive and gram negative agents.

"With a large pipeline of late-stage anti-MRSA products, biopharmaceutical companies are demanding accurate information on MRSA usage patterns and trends so they can understand the current market and how treatments will evolve with the launch of new anti-MRSA drugs," said Joyce Wedemeyer, product director at AMR. "The U.S. Hospital Antibiotic Market Guide allows marketing, new product planning, market research and marketing teams to understand how antibiotic products are used in terms of combination therapy, types of infections, treatment intent and setting, and the types of specialists who are prescribing."

About U.S. Hospital Antibiotic Market Guide

The U.S. Hospital Antibiotic Market Guide is a semiannual syndicated clinical audit of antibacterial use in U.S. acute care hospitals. The audit is based on antibacterial census data from 250 demographically representative hospitals, plus a detailed clinical review of 11,000 randomly selected inpatient records yielding 25,000 antibiotic drug courses each 6-month audit cycle. The Hospital Antibiotic Market Guide is also available for France, Germany, Italy, Spain and the United Kingdom.

About AMR

AMR (http://www.amr-data.com/) is a pharmaceutical market research firm serving the market intelligence needs of the pharmaceutical and diagnostic imaging industries since 1991. With offices in Malvern, PA and Brussels and affiliates in Tokyo, Seoul and Shanghai, AMR publishes syndicated audits for the United States, Italy, Germany, United Kingdom, France, Spain, China, Japan and Korea. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Renal Cell Carcinoma Drug Market Will More than Double Over the Next Decade, Rising from $625 Million in 2007 to Nearly $1.6 Billion in 2017

View Now